Enliven Therapeutics, Inc. Insider Transactions
Enliven Therapeutics, Inc. Insider Trades History
| Insider Name | Buy/Sell | Shares Bought/Sold @ Price |
Total Transaction | Shares Held After Transaction |
Transaction Date | Filing Date | Details |
|---|---|---|---|---|---|---|---|
|
Hohl Benjamin
CFO |
Sell | 900 @ $22.51 | $20,255 | 0 | 12/30/2024 | 12/31/2024 | |
|
Hohl Benjamin
CFO |
Sell | 3,350 @ $22.15 | $74,219 | 0 | 12/27/2024 | 12/31/2024 | |
|
Hohl Benjamin
CFO |
Sell | 4,250 @ $24.78 | $105,313 | 1,000 | 11/27/2024 | 12/02/2024 | |
|
Hohl Benjamin
CFO |
Sell | 1,000 @ $25.38 | $25,376 | 0 | 11/27/2024 | 12/02/2024 | |
|
Hohl Benjamin
CFO |
Sell | 5,600 @ $28.49 | $159,562 | 650 | 10/28/2024 | 10/30/2024 | |
|
Hohl Benjamin
CFO |
Sell | 650 @ $29.11 | $18,922 | 0 | 10/28/2024 | 10/30/2024 | |
|
Patel Anish
CHIEF OPERATING OFFICER |
Sell | 716 @ $30.00 | $21,483 | 343,311 | 10/18/2024 | 10/22/2024 | |
|
Lyssikatos Joseph P
CHIEF SCIENTIFIC OFFICER |
Sell | 847 @ $30.00 | $25,413 | 1,015,188 | 10/18/2024 | 10/22/2024 | |
|
Kintz Samuel
CEO |
Sell | 924 @ $30.00 | $27,723 | 1,002,892 | 10/18/2024 | 10/22/2024 | |
|
Hohl Benjamin
CFO |
Sell | 814 @ $30.00 | $24,422 | 0 | 10/18/2024 | 10/22/2024 | |
|
Heyman Richard A.
Director |
Sell | 817 @ $30.00 | $24,512 | 123,673 | 10/18/2024 | 10/22/2024 | |
|
Heyman Richard A.
Director |
Sell | 753 @ $30.00 | $22,592 | 27,165 | 10/18/2024 | 10/22/2024 | |
|
Collins Helen Louise
CHIEF MEDICAL OFFICER |
Sell | 816 @ $30.00 | $24,482 | 0 | 10/18/2024 | 10/22/2024 | |
|
Heyman Richard A.
Director |
Sell | 1,270 @ $27.67 | $35,143 | 124,490 | 10/15/2024 | 10/17/2024 | |
|
Lyssikatos Joseph P
CHIEF SCIENTIFIC OFFICER |
Sell | 34,289 @ $28.12 | $964,203 | 1,019,624 | 10/09/2024 | 10/10/2024 | |
|
Lyssikatos Joseph P
CHIEF SCIENTIFIC OFFICER |
Sell | 3,589 @ $28.52 | $102,358 | 1,016,035 | 10/09/2024 | 10/10/2024 | |
|
Kintz Samuel
CEO |
Sell | 13,880 @ $28.07 | $389,675 | 1,006,646 | 10/09/2024 | 10/10/2024 | |
|
Kintz Samuel
CEO |
Sell | 2,830 @ $28.53 | $80,730 | 1,003,816 | 10/09/2024 | 10/10/2024 | |
|
Lyssikatos Joseph P
CHIEF SCIENTIFIC OFFICER |
Sell | 13,167 @ $27.96 | $368,173 | 1,054,013 | 10/08/2024 | 10/10/2024 | |
|
Lyssikatos Joseph P
CHIEF SCIENTIFIC OFFICER |
Sell | 100 @ $28.51 | $2,851 | 1,053,913 | 10/08/2024 | 10/10/2024 |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Enliven Therapeutics, Inc. FAQ's
The list of insiders at Enliven Therapeutics, Inc. includes Kintz Samuel, Hohl Benjamin, Lyssikatos Joseph P, Ballal Rahul D., Patel Anish, Collins Helen Louise, Heyman Richard A., Gupta Rishi, ORBIMED ADVISORS LLC.
Insiders have sold a total of 2.69 M Enliven Therapeutics, Inc. shares in the last 12 months for a total of 60.96 M sold.
The following insiders have sold Enliven Therapeutics, Inc. shares in the last 12 months: Kintz Samuel ($4.08 M), Hohl Benjamin ($1.93 M), Lyssikatos Joseph P ($4.16 M), Ballal Rahul D. ($1.99 M), Patel Anish ($1.97 M), Collins Helen Louise ($525,960), Heyman Richard A. ($553,674), Gupta Rishi ($22.88 M), ORBIMED ADVISORS LLC ($22.88 M),